Skip to content

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Ischemic Stroke | Systemic Embolism

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Subjects ≥ 18 years of age
* Documentation of any of the following clinical criteria:

* CHA2DS2-VASc ≥ 4 with age ≥ 65
* CHA2DS2-VASc ≥ 4 with significant left atrium enlargement or elevated NT-proBNP
* CHA2DS2-VASc = 3 with age ≥ 75
* CHA2DS2-VASc = 3 with significant left atrium enlargement or elevated NT-proBNP
* CHA2DS2-VASc score = 2 with age ≥ 65 and significant left atrium enlargement or elevated NT-proBNP

Exclusion Criteria:

* Clinically significant atrial fibrillation or atrial flutter:

* Anytime in the past and
* Documented by an electrocardiographic recording and
* Episode lasting 6 minutes or longer1\*
* Prior procedure involving opening the pericardium or entering the pericardial space
* Prior LAA occlusion, exclusion, or removal (surgical or percutaneous)
* Planned cardiac surgical procedure using non-sternotomy approaches

o Partial sternotomies will be allowed.
* Patients whose planned procedure is a heart transplant or implantation of any ventricular assist devices
* Active endocarditis
* Active systemic infection at the time of cardiac surgery requiring antibiotics, including known SARS-CoV2 infections regardless of symptoms
* Known allergy to Nitinol or nickel sensitivity
* Known medical condition with expected survival of less than 1 year
* Other comorbidities that in the investigator's opinion make the subject unsuitable candidate to complete the protocol required visits.
* Current enrollment in an investigation or trial or an investigational devices or investigational drug that would interfere with this trial.
* Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial.
* Pregnancy
* Known severe symptomatic carotid disease

Study Location

Foothills Medical Centre
Foothills Medical Centre
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Kailey MoenStevens

[email protected]
Hamilton General Hospital
Hamilton General Hospital
Hamilton, Ontario
Canada

Contact Study Team

Primary Contact

Courtney Mullen

[email protected]
905-521-2100
St Michael's Hospital
St Michael's Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Alana Harrington

[email protected]
New Brunswick Heart Centre
New Brunswick Heart Centre
Saint John, New Brunswick
Canada

Contact Study Team

Primary Contact

Dana El-Meghayyar

[email protected]
Ottawa Heart Institute
Ottawa Heart Institute
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Ubabuko Unachukwu

[email protected]
University of Alberta Hospital
University of Alberta Hospital
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Nasim Boroumand

[email protected]
Kingston General Hospital
Kingston General Hospital
Kingston, Ontario
Canada

Contact Study Team

Primary Contact

Sherri Nicol

[email protected]
Toronto General Hospital
Toronto General Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Mousumi Mahanta

[email protected]
Royal Columbian Hospital
Royal Columbian Hospital
New Westminster, British Columbia
Canada

Contact Study Team

Primary Contact

Korey Sutherland

[email protected]
Montreal Heart Institute
Montreal Heart Institute
Montréal, Quebec
Canada

Contact Study Team

Primary Contact

Alexandre Bergeron

[email protected]
London Health Sciences Centre
London Health Sciences Centre
London, Ontario
Canada

Contact Study Team

Primary Contact

Stephanie Fox

[email protected]
Study Sponsored By
AtriCure, Inc.
Participants Required
More Information
Study ID: NCT05478304